Japanese startup Heartseed has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced pluripotent stem, or iPS, cells into patients with severe heart failure.<\/p>\n
The Tokyo-based company, founded by CEO Keiichi Fukuda, professor emeritus of Keio University, hopes to develop a minimally invasive treatment method that does not require surgery.<\/p>\n
The trial was conducted on a patient in his 70s with dilated cardiomyopathy at Shinshu University Hospital in late March, according to an announcement Friday.<\/p>\n
His condition was generally favorable after the injection. He has already been discharged from the hospital.<\/p>\n
In the trial, Heartseed plans to test the procedure on a total of 14 participants by 2029 to verify the safety and effects on heart function.<\/p>\n
The company had developed a treatment involving the surgical transplantation of heart muscle cell masses, called spheroids. In a clinical trial involving 10 patients with severe heart failure, improvements in cardiac function and symptoms were confirmed.<\/p>\n
As no major safety problems have been found with this method, Heartseed aims to apply for pharmaceutical approval to make and sell such spheroids and a device used in the procedure within this year.<\/p>\n
The catheter-based injection is regarded as a next-generation treatment far less invasive than the surgical transplantation.<\/p>\n
\u201cThe biggest advantage of catheters is that they reduce the burden on patients,\u201d Fukuda said. \u201cWe\u2019ll consider the best way to use them.\u201d<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Japanese startup Heartseed has said it conducted a clinical trial to inject via catheter small masses of heart…\n","protected":false},"author":2,"featured_media":39824,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[16684,8,17,29239,9326,29240,5027],"class_list":["post-39823","post","type-post","status-publish","format-standard","has-post-thumbnail","category-japan","tag-ips","tag-japan","tag-japanese","tag-keio-university","tag-medicine","tag-shinshu-university-hospital","tag-startups"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/39823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/comments?post=39823"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/posts\/39823\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media\/39824"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/media?parent=39823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/categories?post=39823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/japan\/wp-json\/wp\/v2\/tags?post=39823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}